Drug Trial Radar · NCT05383196
Onvansertib + Paclitaxel In TNBC
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Sep 30, 2022
Primary completion
Dec 15, 2026
Study completion Feb 15, 2029
Sponsor
- Lead sponsor
- Antonio Giordano, MDAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Cardiff Oncology
- First posted
- May 20, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This research is being done to evaluate the safety and effectiveness of Onvansertib in combination with Paclitaxel in triple-negative breast cancer (TNBC) that has spread to other parts of the body. The names of the study interventions involved in this study are: * Onvansertib * Paclitaxel
Conditions
- Breast Cancer
- Invasive Breast Cancer
- Unresectable Breast Carcinoma
- Locally Advanced Breast Cancer
- Metastatic Breast Cancer
- Inflammatory Breast Cancer
- Triple Negative Breast Cancer (TNBC)
- Hormone Receptor/Growth Factor Receptor-Negative Breast Cancer
- HER2-negative Breast Cancer
- Hormone Receptor Negative Breast Carcinoma
Interventions
OnvansertibDrug
oral administration, once daily for 21 consecutive days, followed by 7 days without drug, to complete a cycle of 28 days.
PaclitaxelDrug
once a week into your vein (by intravenous infusion) over about 30 minutes. This will continue for 3 weeks of every cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-Limiting Toxicity (DLT)-Phase IbTime frame: during the first cycle of therapy (28 days).
- Incidence of Grade 3 or Higher Treatment-Related Toxicity- Phase IbTime frame: during the first cycle of therapy (28 days).
- Overall Response Rate (ORR) Phase IITime frame: Every 8 weeks until disease progression, in average 24 weeks
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Massachusetts General Hospital
Boston, Massachusetts
Beth Israel Deaconness Medical Center
Boston, Massachusetts
Dana-Farber Cancer Institute
Boston, Massachusetts
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.